Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $63.28 (market cap $78.49B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 8.8× Kymera Therapeutics Inc. Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.38% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and MONDELEZ INTERNATIONAL INC Common Stock for 108 Days on average.
| KYMR | MDLZ | |
|---|---|---|
Market Cap | $8.87B | $78.49B |
Volume | 779,107 | 7,021,971 |
Sector | Health | Consumer Staples |
52-Week High | $127.31 | $64.99 |
52-Week Low | $55.80 | $51.51 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $8.26B | $98.84B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mondelez International (MDLZ) trades at $62.57, up 1.26% with strong technical momentum and bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54B in 2025, though net margins compressed to 6.36% from previous highs. Analyst consensus remains strongly bullish with a $70.29 price target, supported by recent dividend increases and strategic expansions.
MDLZ offers stable growth with defensive characteristics amid market volatility. Key opportunities include margin recovery from productivity gains and emerging market expansion. Risks include persistent cocoa cost pressures and competitive snack category dynamics. The stock presents a compelling risk-reward profile for long-term investors seeking quality consumer staples exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
